Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc.

Sep 18 • 04:00PM ET

83.89

Dollar change +0.84
Percentage change 1.01	%

Healthcare • Drug Manufacturers - General • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ SPY IVV VTV XLV IBB COWZ MOAT

Scroll to Statements

Index	NDX, S&P 500	P/E	102.53	EPS (ttm)	0.82	Insider Own	0.21%	Shs Outstand	1.25B	Perf Week	3.64%
Market Cap	104.44B	Forward P/E	11.66	EPS next Y	7.20	Insider Trans	-2.59%	Shs Float	1.24B	Perf Month	12.68%
Income	1.05B	PEG	17.15	EPS next Q	1.56	Inst Own	84.88%	Short Float	1.59%	Perf Quarter	32.84%
Sales	27.78B	P/S	3.76	EPS this Y	-43.67%	Inst Trans	0.85%	Short Ratio	2.83	Perf Half Y	14.28%
Book/sh	14.67	P/B	5.72	EPS next Y	90.11%	ROA	1.82%	Short Interest	19.80M	Perf Year	10.94%
Cash/sh	3.37	P/C	24.88	EPS next 5Y	5.98%	ROE	5.34%	52W Range	62.07 - 87.86	Perf YTD	3.56%
Dividend Est.	3.08 (3.67%)	P/FCF	15.15	EPS past 5Y	1.55%	ROI	2.64%	52W High	-4.52%	Beta	0.19
Dividend TTM	3.06 (3.65%)	Quick Ratio	0.95	Sales past 5Y	4.16%	Gross Margin	77.60%	52W Low	35.15%	ATR (14)	1.66
Dividend Ex-Date	Sep 13, 2024	Current Ratio	1.14	EPS Y/Y TTM	-80.78%	Oper. Margin	36.44%	RSI (14)	75.30	Volatility	2.02% 1.79%
Employees	18000	Debt/Eq	1.28	Sales Y/Y TTM	2.05%	Profit Margin	3.79%	Recom	2.17	Target Price	84.41
Option/Short	Yes / Yes	LT Debt/Eq	1.18	EPS Q/Q	55.31%	Payout	66.62%	Rel Volume	1.32	Prev Close	83.05
Sales Surprise	3.75%	EPS Surprise	25.05%	Sales Q/Q	5.46%	Earnings	Aug 08 AMC	Avg Volume	6.99M	Price	83.89
SMA20	5.95%	SMA50	10.57%	SMA200	14.14%	Trades		Volume	9,198,303	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform	$79 → $82
Oct-28-22	Reiterated	JP Morgan	Overweight	$80 → $87
Oct-28-22	Reiterated	Jefferies	Buy	$78 → $86

Show Previous Ratings

Today 01:30PM	Working to Build Next-Generation Cancer Therapies (ACCESSWIRE)
Sep-17-24 06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why (Zacks)
Sep-16-24 06:00AM	This 'forgotten child' is one of the best biotech plays: Analyst (Yahoo Finance Video)
01:52AM	Gileads lenacapavir: HIV prospects strongest in long-acting combos with Mercks islatravir (Clinical Trials Arena)
Sep-14-24 08:45AM	Got $200? 2 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
01:51AM	Loading…
01:51AM	Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
Sep-13-24 06:55AM	Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial (BioPharma Dive)
Sep-12-24 06:11PM	Why Gilead Sciences Stock Thrashed the Market Today (Motley Fool)
04:05PM	Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention (Investor's Business Daily)
01:46PM	Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections (Benzinga)
10:20AM	Gilead Unveils More Positive Data on HIV Prevention Shot (Barrons.com)
10:07AM	Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug (The Wall Street Journal)
09:45AM	Gilead says HIV prevention injection reduced cases by 96%, sending shares higher (Investing.com)
09:35AM	Helping End HIV - Gilead Sciences (ACCESSWIRE)
08:30AM	Gileads Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada in Second Pivotal Phase 3 Trial (Business Wire)
05:50PM	Loading…
Sep-11-24 05:50PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
03:52AM	Gilead and Genesis partner to create novel therapies using AI (Pharmaceutical Technology)
Sep-10-24 09:20AM	Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company (ACCESSWIRE)
08:00AM	Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies (Business Wire)
Sep-08-24 01:57AM	Gilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock? (Insider Monkey)
Sep-06-24 09:15AM	Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey (ACCESSWIRE)
Sep-05-24 08:00AM	Gilead to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer (Business Wire)
Sep-04-24 09:25AM	Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers (ACCESSWIRE)
06:52AM	Avenzo and Gilead partner for breast cancer combination regimen trial (Clinical Trials Arena)
Aug-30-24 05:34PM	Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. (Barrons.com)
02:05PM	How Gilead Sciences, Virtus Investment And Hess Midstream Could Put Cash In Your Pocket (Benzinga)
01:46AM	Insider Sale: Johanna Mercier Sells 9,513 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia)
Aug-27-24 09:15AM	'The Adventure Jar,' Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together (ACCESSWIRE)
Aug-26-24 01:19PM	Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock? (Zacks)
09:00AM	Loading…
Aug-22-24 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
Aug-21-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
Aug-20-24 02:00PM	How To Earn $100 Per Month From Gilead Sciences Stock (Benzinga)
09:00AM	Gilead Sciences: 'One of Best Employers for Women' by Forbes (ACCESSWIRE)
08:30AM	Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences (ACCESSWIRE)
Aug-19-24 05:12AM	Gilead partners with PANTHERx for LIVDELZI distribution (Pharmaceutical Technology)
Aug-17-24 01:44AM	Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi (Zacks)
Aug-15-24 01:13PM	Gileads PBC therapy Livdelzi bags accelerated approval (Pharmaceutical Technology)
09:09AM	FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal (Benzinga)
06:53AM	FDA clears Gilead drug acquired in $4.3B buyout (BioPharma Dive)
Aug-14-24 05:01PM	Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
01:59PM	Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA (Business Wire)
Aug-13-24 08:45AM	Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia (ACCESSWIRE)
Aug-10-24 06:50AM	3 Stocks Retirees Should Absolutely Love (Motley Fool)
Aug-09-24 04:34PM	These Stocks Moved the Most Today: Expedia, Akamai, Lilly, E.l.f. Beauty, Doximity, Rocket Lab, Five9, Array, and More (Barrons.com)
04:11PM	Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat (Investor's Business Daily)
02:43PM	These Stocks Are Moving the Most Today: Expedia, Akamai, Lilly, E.l.f. Beauty, Doximity, Rocket Lab, Five9, Array, and More (Barrons.com)
12:22PM	Q2 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
11:15AM	These Stocks Are Moving the Most Today (Barrons.com)
09:45AM	Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised (Zacks)
08:23AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
06:52AM	Gilead Sciences reports net income rise in Q2 2024 (Pharmaceutical Technology)
01:12AM	Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 09:45PM	Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:16PM	Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations (Investor's Business Daily)
05:15PM	Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat (Investor's Business Daily)
04:12PM	Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment (Barrons.com)
04:11PM	Gilead: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Gilead quarterly profit beats Street estimates, revenue up 5% (Reuters)
04:02PM	Gilead Sciences Announces Second Quarter 2024 Financial Results (Business Wire)
10:15AM	Closing the HIV Diagnosis Gap in Germany with Gilead Sciences (ACCESSWIRE)
Aug-07-24 09:01AM	Gilead Sciences Inc (GILD) Q2 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-05-24 09:16AM	Countdown to Gilead (GILD) Q2 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
Aug-04-24 08:00AM	What To Expect in the Markets This Week (Investopedia)
Aug-03-24 06:45AM	2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off (Motley Fool)
Aug-02-24 03:33PM	Q3s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List (InvestorPlace)
09:25AM	Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings? (Zacks)
Aug-01-24 05:50PM	Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors (Zacks)
10:01AM	Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-31-24 04:30PM	The Top 3 Biotech Stocks to Buy Now Summer 2024 (InvestorPlace)
09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
Jul-30-24 06:52AM	Compugen receives FDA approval for Phase I trial of solid tumour treatment (Clinical Trials Arena)
Jul-29-24 06:00PM	Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jul-25-24 04:05PM	Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (Business Wire)
09:15AM	Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline (Business Wire)
06:15AM	3 Stocks That Can Help You to Get Richer in 2024 and Beyond (Motley Fool)
Jul-24-24 04:30AM	Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 (Business Wire)
Jul-23-24 01:00PM	Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire (Benzinga)
06:32AM	ViiV Healthcares Dovato as effective as Biktarvy in Phase IV HIV trial (Clinical Trials Arena)
03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-22-24 06:00PM	Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors (Zacks)
01:54PM	UNAIDS boss calls on Gilead to provide miracle drug to developing countries (Pharmaceutical Technology)
04:00AM	Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia (Business Wire)
Jul-18-24 05:45PM	T-Mobile US, Inc. (TMUS): Why Are Hedge Funds Bullish on This Communication and Media Stock Right Now? (Insider Monkey)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jul-17-24 08:50AM	Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025 (Business Wire)
07:15AM	Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays (Motley Fool)
05:52AM	Gilead set to unveil data from HIV/AIDS trials (Clinical Trials Arena)
Jul-16-24 06:00PM	Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
08:30AM	Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024 (Business Wire)
Jul-15-24 07:34PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
10:51AM	The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 (InvestorPlace)
Jul-14-24 06:30AM	3 Dividend Growth Stocks to Buy and Hold (Motley Fool)
Jul-13-24 11:00AM	The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 (InvestorPlace)
Jul-11-24 10:30AM	3 Underappreciated Stocks About to Break Their Chains (InvestorPlace)
Jul-10-24 06:00PM	Why Gilead Sciences (GILD) Outpaced the Stock Market Today (Zacks)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 12:03PM	Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data (Investopedia)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003	Oct 18 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc.

Upgrade your FINVIZ experience